Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium longum GDMCC No.60310
- Development stage
- Unknown
- Lead developer
- Tinghu District People's Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum GDMCC No.60310 is a live biotherapeutic product (LBP) consisting of a specific strain of the commensal bacterium *Bifidobacterium longum*. It is being developed by The Peoples' Hospital of Tinghu District of Yancheng City for the treatment of ulcerative colitis (UC). The strain was isolated and deposited in the Guangdong Microbial Culture Collection Center (GDMCC). Its therapeutic potential lies in its ability to restore gut microbial homeostasis, strengthen the intestinal mucosal barrier, and exert immunomodulatory effects. By producing metabolites such as short-chain fatty acids (SCFAs) and interacting with the gut-associated lymphoid tissue, it aims to suppress the production of pro-inflammatory cytokines (e.g., TNF-alpha, IL-6) and promote an anti-inflammatory environment in the colon, thereby inducing or maintaining remission in UC patients.
- Other names
- Bifidobacterium longum strain GDMCC 60310
Beyond the preview
Go deeper on bifidobacterium longum GDMCC No.60310.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium longum GDMCC No.60310.